JosÃ MarÃa Rojas CabaÃ‘eros

List of Publications by Year
in descending order

48 papers	1,794 citations	236925 25 h-index	265206 42 g-index
48 all docs	48 docs citations	48 times ranked	2801 citing authors

#	Article	IF	Citations
1	The CSN3 subunit of the COP9 signalosome interacts with the HD region of Sos1 regulating stability of this GEF protein. Oncogenesis, 2019, 8, 2.	4.9	12
2	PGA1-induced apoptosis involves specific activation of H-Ras and N-Ras in cellular endomembranes. Cell Death and Disease, 2016, 7, e2311-e2311.	6.3	7
3	SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. Oncogene, 2016, 35, 2991-3003.	5.9	40
4	Shoc2/Sur8 Protein Regulates Neurite Outgrowth. PLoS ONE, 2014, 9, e114837.	2.5	1
5	Regulation of CBP and Tip60 coordinates histone acetylation at local and global levels during Ras-induced transformation. Carcinogenesis, 2014, 35, 2194-2202.	2.8	11
6	Intersectin 1 Enhances Cbl Ubiquitylation of Epidermal Growth Factor Receptor through Regulation of Sprouty2-Cbl Interaction. Molecular and Cellular Biology, 2012, 32, 817-825.	2.3	21
7	Mammalian Son of Sevenless Guanine Nucleotide Exchange Factors: Old Concepts and New Perspectives. Genes and Cancer, 2011, 2, 298-305.	1.9	66
8	The C-Terminus of H-Ras as a Target for the Covalent Binding of Reactive Compounds Modulating Ras-Dependent Pathways. PLoS ONE, 2011, 6, e15866.	2.5	30
9	Sprouty2 and Spred1-2 Proteins Inhibit the Activation of the ERK Pathway Elicited by Cyclopentenone Prostanoids. PLoS ONE, 2011, 6, e16787.	2.5	4
10	SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene, 2010, 29, 4800-4813.	5.9	63
11	Cell Density-Dependent Inhibition of Epidermal Growth Factor Receptor Signaling by p38Î± Mitogen-Activated Protein Kinase via Sprouty2 Downregulation. Molecular and Cellular Biology, 2009, 29, 3332-3343.	2.3	52
12	SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochemical Pharmacology, 2009, 77, 965-978.	4.4	54
13	Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas. Oncogene, 2008, 27, 4969-4972.	5.9	25
14	Plitidepsin Has a Dual Effect Inhibiting Cell Cycle and Inducing Apoptosis via Rac1/c-Jun NH₂-Terminal Kinase Activation in Human Melanoma Cells. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 1093-1101.	2.5	45
15	E1a Gene Expression Blocks the ERK1/2 Signaling Pathway by Promoting Nuclear Localization and MKP Up-regulation. Journal of Biological Chemistry, 2008, 283, 13450-13458.	3.4	17
16	Nuclear Exclusion of Forkhead Box O and Elk1 and Activation of Nuclear Factor-ÎºB Are Required for C2C12-RasV12C40 Myoblast Differentiation. Endocrinology, 2008, 149, 793-801.	2.8	10
17	Endothelial nitric oxide synthase regulates N-Ras activation on the Golgi complex of antigen-stimulated T cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10507-10512.	7.1	71
18	Modification and Activation of Ras Proteins by Electrophilic Prostanoids with Different Structure are Site-Selective. Biochemistry, 2007, 46, 6607-6616.	2.5	62

#	Article	IF	Citations
19	Sprouty2 binds Grb2 at two different proline-rich regions, and the mechanism of ERK inhibition is independent of this interaction. Cellular Signalling, 2007, 19, 2277-2285.	3.6	22
20	The histone acetyltransferases CBP/p300 are degraded in NIH 3T3 cells by activation of Ras signalling pathway. Biochemical Journal, 2006, 398, 215-224.	3.7	25
21	AplidinÂ® induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death and Differentiation, 2006, 13, 1968-1981.	11.2	73
22	Potentiation of tumor formation by topical administration of 15-deoxy-Î” 12,14 -prostaglandin J 2 in a model of skin carcinogenesis. Carcinogenesis, 2006, 27, 328-336.	2.8	37
23	Grb2 Is a Negative Modulator of the Intrinsic Ras-GEF Activity of hSos1. Molecular Biology of the Cell, 2006, 17, 3591-3597.	2.1	46
24	Plitidepsin Cellular Binding and Rac1/JNK Pathway Activation Depend on Membrane Cholesterol Content. Molecular Pharmacology, 2006, 70, 1654-1663.	2.3	24
25	Ras-Gefs and Ras Gaps. , 2006, , 15-43.		6
26	Sprouty-2 Overexpression in C2C12 Cells Confers Myogenic Differentiation Properties in the Presence of FGF2. Molecular Biology of the Cell, 2005, 16, 4454-4461.	2.1	49
27	Full Activation of PKB/Akt in Response to Insulin or Ionizing Radiation Is Mediated through ATM. Journal of Biological Chemistry, 2005, 280, 4029-4036.	3.4	231
28	Immortalized Mouse Mammary Fibroblasts Lacking Dioxin Receptor Have Impaired Tumorigenicity in a Subcutaneous Mouse Xenograft Model. Journal of Biological Chemistry, 2005, 280, 28731-28741.	3.4	87
29	The P34G Mutation Reduces the Transforming Activity of K-Ras and N-Ras in NIH 3T3 Cells but Not of H-Ras. Journal of Biological Chemistry, 2004, 279, 33480-33491.	3.4	26
30	Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer. International Journal of Cancer, 2003, 107, 781-790.	5.1	48
31	H-Ras-specific activation of NF-Î°B protects NIH 3T3 cells against stimulus-dependent apoptosis. Oncogene, 2003, 22, 477-483.	5.9	27
32	The cyclopentenone 15-deoxy-Î” ^{12,14} -prostaglandin J ₂ binds to and activates H-Ras. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4772-4777.	7.1	124
33	hSos1 Contains a New Amino-terminal Regulatory Motif with Specific Binding Affinity for Its Pleckstrin Homology Domain. Journal of Biological Chemistry, 2002, 277, 44171-44179.	3.4	25
34	Genetic analysis ofRET, GFRÎ±1andGDNFgenes in Spanish families with multiple endocrine neoplasia type 2A. International Journal of Cancer, 2002, 99, 299-304.	5.1	34
35	ras Genes and Human Cancer: Different Implications and Different Roles. Current Genomics, 2002, 3, 295-311.	1.6	25
36	The isoform-specific stretch of hSos1 defines a new Grb2-binding domain. Oncogene, 2000, 19, 5872-5883.	5.9	19

#	Article	IF	Citations
37	p53/MDM2 Pathway Aberrations in Parathyroid Tumors: p21^{WAF-1} and MDM2 Are Frequently Overexpressed in Parathyroid Adenomas. Endocrine Pathology, 2000, 11, 251-258.	9.0	7
38	Analysis of the Cyclin D1/p16/pRb Pathway in Parathyroid Adenomas. Endocrine Pathology, 2000, 11, 259-266.	9.0	4
39	Isoform-specific insertion near the Grb2-binding domain modulates the intrinsic guanine nucleotide exchange activity of hSos1. Oncogene, 1999, 18, 1651-1661.	5.9	13
40	Transformation suppressor activity of C3G is independent of its CDC25-homology domain. Oncogene, 1998, 16, 613-624.	5.9	40
41	Isolated Sos1 PH Domain Exhibits Germinal Vesicle Breakdown-inducing Activity in Oocytes. Journal of Biological Chemistry, 1996, 271, 18272-18276.	3.4	10
42	Genetic Analysis of Herpes Simplex Virus Type 1 Isolates from Recurrent Lesions and Clinical Reinfections. Journal of Infectious Diseases, 1995, 172, 1602-1605.	4.0	5
43	Comparative study of the genetic variability in thymidine kinase and glycoprotein B genes of herpes simplex viruses by the RNase A mismatch cleavage method. Virus Research, 1995, 35, 205-214.	2.2	10
44	Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates. AIDS Research and Human Retroviruses, 1994, 10, 1479-1488.	1.1	89
45	Molecular epidemiology of HIV-1 in Madrid. Virus Research, 1994, 31, 331-342.	2.2	18
46	Analysis of genetic variability of populations of herpes simplex viruses. Virus Research, 1993, 28, 249-261.	2.2	10
47	Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 4280-4284.	7.1	69
48	Evaluation of three methods for typing herpes simpex viras. European Journal of Clinical Microbiology and Infectious Diseases, 1987, 6, 664-667.	2.9	0